[go: up one dir, main page]

CY1119746T1 - Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων - Google Patents

Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων

Info

Publication number
CY1119746T1
CY1119746T1 CY20181100017T CY181100017T CY1119746T1 CY 1119746 T1 CY1119746 T1 CY 1119746T1 CY 20181100017 T CY20181100017 T CY 20181100017T CY 181100017 T CY181100017 T CY 181100017T CY 1119746 T1 CY1119746 T1 CY 1119746T1
Authority
CY
Cyprus
Prior art keywords
procedures
treatment
taking
intestinal diseases
rifaximin
Prior art date
Application number
CY20181100017T
Other languages
English (en)
Inventor
Viscomi Giuseppe Claudio
Maffei Paola
Bottoni Giuseppe
Grimaldi Maria
Original Assignee
Alfasigma S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43737853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119746(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfasigma S.P.A. filed Critical Alfasigma S.P.A.
Publication of CY1119746T1 publication Critical patent/CY1119746T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Το αντικείμενο της εφεύρεσης αφορά γαστροανθεκτικά δισκία που περιέχουν ριφαξιμίνη, η οποία λαμβάνεται μέσω γαστροανθεκτικών μικροκόκκων, που χαρακτηρίζονται από το ότι αναστέλλουν την απελευθέρωση ριφαξιμίνης σε τιμές pΗ ανάμεσα σε 1,5 και 4,0 και επιτρέπουν την απελευθέρωση της σε τιμές pΗ ανάμεσα σε 5,0 και 7,5, τις διαδικασίες για τη λήψη τους και τη χρήση τους στην αγωγή και την πρόληψη νόσων που παράγονται άμεσα ή έμμεσα από φλεγμονώδεις εντερικές νόσους.
CY20181100017T 2010-09-22 2018-01-08 Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων CY1119746T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITBO20100567 2010-09-22
ITBO20100638 2010-10-22
ITBO2011A000012A IT1403847B1 (it) 2010-09-22 2011-01-19 Composizioni farmaceutiche comprendenti rifaximina e loro uso.
PCT/IB2011/054133 WO2012038898A1 (en) 2010-09-22 2011-09-21 Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease

Publications (1)

Publication Number Publication Date
CY1119746T1 true CY1119746T1 (el) 2018-06-27

Family

ID=43737853

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100017T CY1119746T1 (el) 2010-09-22 2018-01-08 Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων

Country Status (31)

Country Link
US (4) US20120245192A1 (el)
EP (1) EP2618819B1 (el)
JP (1) JP5918242B2 (el)
KR (2) KR102049253B1 (el)
CN (1) CN103118666A (el)
AU (1) AU2011306444B2 (el)
BR (1) BR112013007457A8 (el)
CA (1) CA2809509C (el)
CL (1) CL2013000677A1 (el)
CO (1) CO6680695A2 (el)
CY (1) CY1119746T1 (el)
DK (1) DK2618819T3 (el)
EA (1) EA027588B1 (el)
ES (1) ES2649063T3 (el)
HR (1) HRP20171734T1 (el)
HU (1) HUE034620T2 (el)
IL (1) IL271927A (el)
IT (1) IT1403847B1 (el)
LT (1) LT2618819T (el)
ME (1) ME03044B (el)
MX (1) MX349719B (el)
NO (1) NO2618819T3 (el)
PL (1) PL2618819T3 (el)
PT (1) PT2618819T (el)
RS (1) RS56708B1 (el)
SG (2) SG188271A1 (el)
SI (1) SI2618819T1 (el)
TN (1) TN2013000073A1 (el)
UA (1) UA110212C2 (el)
WO (1) WO2012038898A1 (el)
ZA (1) ZA201301391B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
MX374340B (es) * 2013-04-12 2025-03-06 Alfasigma Spa Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
US20160206564A1 (en) * 2013-09-27 2016-07-21 Ira Milton Trachtman Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
JP6608193B2 (ja) * 2014-06-27 2019-11-20 花王株式会社 固形状組成物
WO2016063289A2 (en) * 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
CN110072525B (zh) * 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式
PL3416627T3 (pl) * 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
BR112021004213A2 (pt) 2018-09-06 2021-05-25 Fachhochschule Nordwestschweiz forma de dosagem de formulação farmacêutica e método para preparar uma forma de dosagem de formulação farmacêutica
BR112022003500A2 (pt) * 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2008035108A1 (en) 2006-09-21 2008-03-27 Ray Mason Engine assemblies
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
ITBO20110012A1 (it) 2012-03-23
LT2618819T (lt) 2018-02-26
CA2809509A1 (en) 2012-03-29
CO6680695A2 (es) 2013-05-31
PL2618819T3 (pl) 2018-01-31
US20150080421A1 (en) 2015-03-19
EP2618819B1 (en) 2017-11-01
HUE034620T2 (en) 2018-02-28
US20120245192A1 (en) 2012-09-27
BR112013007457A2 (pt) 2016-07-12
ME03044B (me) 2018-10-20
US20210244714A1 (en) 2021-08-12
SG10201507869UA (en) 2015-10-29
WO2012038898A1 (en) 2012-03-29
DK2618819T3 (en) 2017-12-11
IT1403847B1 (it) 2013-11-08
JP2013537900A (ja) 2013-10-07
KR102049253B1 (ko) 2019-11-28
JP5918242B2 (ja) 2016-05-18
KR20180001586A (ko) 2018-01-04
HRP20171734T1 (hr) 2018-01-26
EA201390310A1 (ru) 2013-11-29
BR112013007457A8 (pt) 2017-12-26
CA2809509C (en) 2016-04-26
CL2013000677A1 (es) 2013-07-19
AU2011306444A1 (en) 2013-03-21
ZA201301391B (en) 2014-04-30
NO2618819T3 (el) 2018-03-31
MX2013003243A (es) 2013-05-22
US20170071916A1 (en) 2017-03-16
IL271927A (en) 2020-02-27
CN103118666A (zh) 2013-05-22
TN2013000073A1 (en) 2014-06-25
SG188271A1 (en) 2013-04-30
AU2011306444B2 (en) 2015-04-23
SI2618819T1 (en) 2018-01-31
EP2618819A1 (en) 2013-07-31
ES2649063T3 (es) 2018-01-09
RS56708B1 (sr) 2018-03-30
UA110212C2 (uk) 2015-12-10
EA027588B1 (ru) 2017-08-31
PT2618819T (pt) 2017-12-11
KR20130106400A (ko) 2013-09-27
MX349719B (es) 2017-08-09

Similar Documents

Publication Publication Date Title
CY1119746T1 (el) Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων
CY1124068T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1121465T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
DK2170930T3 (da) Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
EP3871639C0 (en) GASTRO-SOPHAGEAL REFLUX TREATMENT DEVICE
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
MX375902B (es) Inhibidores de serina/treonina cinasa.
EA201290642A1 (ru) Соединения и способы
EA201170040A1 (ru) Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и способы их получения и применения
EA201201665A1 (ru) Новые соединения
IN2012DN02737A (el)
EP2276541A4 (en) MAINTAINING THROMBOZYTE INHIBITION DURING THROMBYTIC THERAPY
EP2415763A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
DK3708192T3 (da) Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
EA201201324A1 (ru) Профилактика колоректального и желудочно-кишечного рака
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств
GB2490853A (en) Polyimidazoles for use as bile acid sequestrants
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του
GB2490855A (en) Amine polymers for use as bile acid sequestrants
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5